Biocept (FRA:B00) Change In Receivables : €11.52 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocept Change In Receivables?

Biocept's change in receivables for the quarter that ended in Jun. 2023 was €0.29 Mil. It means Biocept's Accounts Receivable declined by €0.29 Mil from Mar. 2023 to Jun. 2023 .

Biocept's change in receivables for the fiscal year that ended in Dec. 2022 was €10.98 Mil. It means Biocept's Accounts Receivable declined by €10.98 Mil from Dec. 2021 to Dec. 2022 .

Biocept's Accounts Receivable for the quarter that ended in Jun. 2023 was €0.74 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biocept's Days Sales Outstanding for the three months ended in Jun. 2023 was 123.79.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biocept's liquidation value for the three months ended in Jun. 2023 was €-13.20 Mil.

Biocept Change In Receivables Historical Data

The historical data trend for Biocept's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Change In Receivables Chart

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.34

-1.76

-8.73

0.32

10.98

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Receivables	Get a 7-Day Free Trial															3.56	6.25	4.01	0.97	0.29

Biocept Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.52 Mil.

Biocept (FRA:B00) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biocept's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.738	/	0.544	*	91
=	123.79

2. In Ben Graham's calculation of liquidation value, Biocept's accounts receivable are only considered to be worth 75% of book value:

Biocept's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.122	-	20.133	+	0.75 * 0.738	+	0.5 * 0.509
=	-13.20

Biocept Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biocept's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines